BioSpace News Archive

Companies from across the globe provide updates on their businesses and pipelines.

The Association for the Accreditation of Human Research Protection Programs announced that it has awarded full accreditation to Principal IRB, Inc., in Deland, Florida.

Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for a new patent application covering ALLOCETRATM, the company’s immunotherapy product candidate.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company’s expanded access protocol (“EAP”) for compassionate use of Bucillamine in the treatment of COVID-19 received approval from the independent Institutional Review Board (“IRB”).

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board (DSMB) has unanimously approved the continuation of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The DSMB is a committee of clinical research experts,

Galenagen, LLC, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,776,453 relating to remote monitoring of Parkinson’s Disease. Galenagen’

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host an R&D Day on Wednesday, September 30, 2020. The event is scheduled to take place from 10:00 a.m. to 12:30 p.m. ET in a virtual format.

Blue Cross Blue Shield of Massachusetts , Inc. (“Blue Cross”) has received two Stevie International Business Awards for the company’s health news service, Coverage , in recognition of the valuable information it has provided as a public service during the COVID-19 pandemic.

- Treatment with olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy shows promising overall survival benefit in this heavily pretreated late-stage patient population - The majority of patients benefited from apparent reversal of platinum resistance with preserved or improved performance status - Olvi-Vec treatment was tolerated with safety results consistent with previous Phase 1b study

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the complete dataset on the primary endpoint from its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (MIRROR) open-label trial in the Journal of Rheumatology [https://doi.org/10.3899/jrheum.200460].